Is MYO or RGNT more undervalued in 2026?

CirclFi compares Myomo Inc. (MYO) and Regentis Biomaterials Ltd. (RGNT) using 13 institutional-grade valuation models. MYO has a Quality of Company score of 6.7/10 while RGNT scores 3.6/10.

Which is a better buy — MYO or RGNT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MYO and RGNT valuations compare?

MYO at $1.09 and RGNT at $1.85 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MYO vs RGNT Valuation Comparison 2026 — Intrinsic Value Analysis

MYO

Orthopedic, Prosthetic & Surgical Appliances & Supplies

Myomo Inc.

Quality

6.7

out of 10

Value Trap

LOW

Price

$1.09

Last close

Models

11/13

Active

RGNT

Orthopedic, Prosthetic & Surgical Appliances & Supplies

Regentis Biomaterials Ltd.

Quality

3.6

out of 10

Value Trap

—

Price

$1.85

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	MYO Fair Value	MYO Upside	RGNT Fair Value	RGNT Upside
Bayesian DCF	Intrinsic	$0.20	-81.8%	$2.06	-19.4%
Earnings Power Value	Intrinsic	$1.87	+107.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.20	-81.5%	$0.32	-89.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MYO vs RGNT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MYO vs RGNT — Which Stock Is More Undervalued?

MYO scores higher with a 6.7/10 quality rating vs RGNT's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Myomo Inc. (MYO) and Regentis Biomaterials Ltd. (RGNT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MYO currently trades at $1.09 with a QOC of 6.7/10, while RGNT trades at $1.85 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).